Xention Participates in €12 Million Atrial Fibrillation Research Consortium

Consortium awarded five-year European Union grant under Seventh Framework programme

17-Mar-2011 - United Kingdom

XENTION LTD announced that it is a partner in a new multidisciplinary atrial fibrillation research consortium, the ‘European Network for Translational Research in Atrial Fibrillation’ (EUTRAF), which has been awarded a €12 million grant to engage in atrial fibrillation (AF) research.

The consortium will undertake a five-year research project with the objective of improving the diagnosis, prevention and treatment of AF through the application of a highly integrative research approach.

‘Xention has a broad programme of research and development in atrial fibrillation and is delighted to participate in this consortium with a network of highly respected scientific institutions and clinical experts’ said Tim Brears CEO of Xention.  Xention’s role in the consortium will be to characterize molecular biomarkers of abnormal function of ion channels known to play a role in atrial fibrillation, to validate newly identified ion channels that may have therapeutic potential in AF and to identify pharmacological tools to validate such channels.



Other news from the department science

More news from our other portals

All FT-IR spectrometer manufacturers at a glance